Metabolomics combined with network pharmacology reveals a role for astragaloside IV in inhibiting enterovirus 71 replication via PI3K-AKT signaling

JinFang Hao,Xiaoyan Zhang,Ruixian Hu,Xiufeng Lu,Hui Wang,Yuanhong Li,Kai Cheng,Qingshan Li
DOI: https://doi.org/10.1186/s12967-024-05355-9
IF: 8.44
2024-06-12
Journal of Translational Medicine
Abstract:Astragaloside IV (AST-IV), as an effective active ingredient of Astragalus membranaceus (Fisch.) Bunge. It has been found that AST-IV inhibits the replication of dengue virus, hepatitis B virus, adenovirus, and coxsackievirus B3. Enterovirus 71 (EV71) serves as the main pathogen in severe hand-foot-mouth disease (HFMD), but there are no specific drugs available. In this study, we focus on investigating whether AST-IV can inhibit EV71 replication and explore the potential underlying mechanisms.
medicine, research & experimental
What problem does this paper attempt to address?
This paper aims to investigate whether Astragaloside IV (AST-IV) can inhibit the replication of Enterovirus 71 (EV71) and explore its potential mechanisms of action. EV71 is one of the main pathogens causing hand, foot, and mouth disease, but there are currently no specific drugs available. The study found through cell experiments that AST-IV can effectively inhibit the replication of EV71 and achieve this effect by regulating metabolite levels and activating the PI3K-AKT signaling pathway. Specifically, AST-IV increases the levels of metabolites such as hypoxanthine, 2-ketobutyric acid, and adenine, reduces oxidative stress response, and inhibits EV71-induced apoptosis. These results suggest that AST-IV may be a potential new drug candidate for the treatment of EV71 infection.